Zentalis Pharmaceuticals Llc Stock Performance
| ZNTL Stock | USD 3.14 0.14 4.67% |
The firm maintains a market beta of 3.04, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Zentalis Pharmaceuticals will likely underperform. At this point, Zentalis Pharmaceuticals has a negative expected return of -0.26%. Please make sure to check out Zentalis Pharmaceuticals' maximum drawdown, daily balance of power, as well as the relationship between the Daily Balance Of Power and period momentum indicator , to decide if Zentalis Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Zentalis Pharmaceuticals Llc has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain quite persistent which may send shares a bit higher in November 2024. The latest mess may also be a sign of long-standing up-swing for the company institutional investors. ...more
Actual Historical Performance (%)
One Day Return 4.67 | Five Day Return 5.72 | Year To Date Return (80.36) | Ten Year Return (86.47) | All Time Return (86.47) |
1 | Newman Ferrara LLP Announces Corporate Governance Investigation of Zentalis Pharmaceuticals, Inc. ZNTL | 08/19/2024 |
2 | Zentalis Plunges More Than 70 percent in 3 Months Heres Why - Zacks Investment Research | 08/26/2024 |
3 | Zentalis Pharmaceuticals to Present Preclinical Azenosertib Data at ESMO 2024 | 09/09/2024 |
4 | Insider Trading | 09/12/2024 |
5 | FDA Removes Partial Hold On Zentalis Pharmaceuticals Azenosertib Studies In Patients With Gynecological Cancers | 09/16/2024 |
6 | Zentalis Stock Up as FDA Lifts Partial Hold on Cancer Drug Studies | 09/17/2024 |
7 | Decheng Capital LLC Has 12.56 Million Stock Holdings in Zentalis Pharmaceuticals, Inc. - MarketBeat | 09/26/2024 |
8 | Disposition of 1603 shares by Vincent Vultaggio of Zentalis Pharmaceuticals at 3.18 subject to Rule 16b-3 | 10/04/2024 |
9 | FMR LLC Adjusts Its Stake in Zentalis Pharmaceuticals Inc | 10/07/2024 |
10 | Acquisition by Roth Iris of 297500 shares of Zentalis Pharmaceuticals at 18.87 subject to Rule 16b-3 | 10/11/2024 |
11 | State Street Corps Strategic Reduction in Zentalis Pharmaceuticals Holdings | 10/18/2024 |
| Begin Period Cash Flow | 43.1 M |
Zentalis |
Zentalis Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 401.00 in Zentalis Pharmaceuticals Llc on July 21, 2024 and sell it today you would lose (87.00) from holding Zentalis Pharmaceuticals Llc or give up 21.7% of portfolio value over 90 days. Zentalis Pharmaceuticals Llc is currently does not generate positive expected returns and assumes 4.9081% risk (volatility on return distribution) over the 90 days horizon. In different words, 43% of stocks are less volatile than Zentalis, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Zentalis Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Zentalis Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Zentalis Pharmaceuticals Llc, and traders can use it to determine the average amount a Zentalis Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0526
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ZNTL |
Estimated Market Risk
| 4.91 actual daily | 43 57% of assets are more volatile |
Expected Return
| -0.26 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.05 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Zentalis Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Zentalis Pharmaceuticals by adding Zentalis Pharmaceuticals to a well-diversified portfolio.
Zentalis Pharmaceuticals Fundamentals Growth
Zentalis Stock prices reflect investors' perceptions of the future prospects and financial health of Zentalis Pharmaceuticals, and Zentalis Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Zentalis Stock performance.
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.25 | ||||
| Operating Margin | (5.44) % | ||||
| Current Valuation | 217.67 M | ||||
| Shares Outstanding | 71.11 M | ||||
| Price To Book | 0.56 X | ||||
| Price To Sales | 5.50 X | ||||
| EBITDA | (247.6 M) | ||||
| Net Income | (292.19 M) | ||||
| Cash And Equivalents | 455.22 M | ||||
| Cash Per Share | 7.99 X | ||||
| Total Debt | 45.77 M | ||||
| Debt To Equity | 0.1 % | ||||
| Current Ratio | 9.61 X | ||||
| Book Value Per Share | 5.38 X | ||||
| Cash Flow From Operations | (207.82 M) | ||||
| Earnings Per Share | (2.64) X | ||||
| Market Capitalization | 223.28 M | ||||
| Total Asset | 562.03 M | ||||
| Retained Earnings | (888.56 M) | ||||
| Working Capital | 427.35 M | ||||
About Zentalis Pharmaceuticals Performance
By examining Zentalis Pharmaceuticals' fundamental ratios, stakeholders can obtain critical insights into Zentalis Pharmaceuticals' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Zentalis Pharmaceuticals is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -1.6 K | -1.7 K | |
| Return On Tangible Assets | (0.52) | (0.55) | |
| Return On Capital Employed | (0.51) | (0.53) | |
| Return On Assets | (0.52) | (0.55) | |
| Return On Equity | (0.67) | (0.70) |
Things to note about Zentalis Pharmaceuticals performance evaluation
Checking the ongoing alerts about Zentalis Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Zentalis Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Zentalis Pharmaceuticals generated a negative expected return over the last 90 days | |
| Zentalis Pharmaceuticals has high historical volatility and very poor performance | |
| Net Loss for the year was (292.19 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Zentalis Pharmaceuticals Llc currently holds about 455.22 M in cash with (207.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.99, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Zentalis Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 97.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from gurufocus.com: State Street Corps Strategic Reduction in Zentalis Pharmaceuticals Holdings |
- Analyzing Zentalis Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Zentalis Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Zentalis Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Zentalis Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Zentalis Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Zentalis Pharmaceuticals' stock. These opinions can provide insight into Zentalis Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zentalis Pharmaceuticals Llc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zentalis Pharmaceuticals. If investors know Zentalis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zentalis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.64) | Revenue Per Share 0.572 | Return On Assets (0.25) | Return On Equity (0.43) |
The market value of Zentalis Pharmaceuticals is measured differently than its book value, which is the value of Zentalis that is recorded on the company's balance sheet. Investors also form their own opinion of Zentalis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zentalis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zentalis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zentalis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zentalis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zentalis Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zentalis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.